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This review compares acute myocardial infarction and acute stroke— their similarities and
differences. The focus is given on reperfusion therapy: pharmacologic, mechanical or
combined. The key trials and metaanalyses are described.
The published data on iv. thrombolysis show, that even among a subgroup of patients
treated within 90 min from stroke onset the trend to lower mortality is not significant and
in all other subgroups (i.e. treated after 490 min) there is a trend towards increased
mortality with thrombolytic treatment.
The data on combined therapy demonstrate, that there is no benefit from facilitated
intervention (iv. thrombolysis followed by ia. thrombolysis 7 catheter intervention)
over iv. thrombolysis alone in acute stroke. This is very similar to the situation in
acute myocardial infarction 25 years ago (intracoronary thrombolysis was not superior to
intravenous thrombolysis) or more recently (facilitated PCI was not shown to be superior in
several trials).
The latest generation of stent retrievers is able to recanalize470% of occluded intracranial
arteries—approximately twice more compared to thrombolysis. However, it is not yet known
whether this translates to better clinical outcomes. The sufficient data on clinical outcomes
after primary catheter-based thrombectomy (without thrombolysis) are still missing and
trials comparing iv. thrombolysis versus primary catheter-based thrombectomy are urgently
needed.
The future trials in acute stroke may follow the way paved by acute myocardial infarction
trials. If such trials would demonstrate superiority of catheter-based thrombectomy, we can
face in future similar revolution in acute stroke treatment as we have been facing in acute MI
treatment in the past years.
& 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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Acute myocardial infarction and acute stroke are two single
most frequent causes of death or severe permanent disability
worldwide. 20 years ago both these acute disorders caused
extremely high mortality—between 20% and 30% among
unselected hospital admissions. While cardiologists suc-
ceeded to decrease the in-hospital mortality of unselected
acute myocardial infarction to current cca 5–8% during the
last 20 years, mortality of acute stroke remained largely
unchanged. The dramatic fall of mortality due to acute
myocardial infarction was enabled by the introduction of
reperfusion therapy: initially thrombolysis and later primary
percutaneous coronary intervention (p-PCI). Specifically, the
introduction of STEMI networks (effective regional coopera-
tion between emergency medical services, local community
hospitals and a tertiary cardiac center) contributed to one of
the major breakthroughs in medicine changing a deadly
disease into a treatable one. Many cardiologists worldwide
(after having fully developed STEMI networks in their regions)
are increasingly interested in acute stroke treatment.
The interventional treatment of acute stroke requires effec-
tive cooperation between several medical specialties. This
short review was prepared jointly by one cardiologist, one
radiologist and three neurologists and deals with similarities
and differences between the two diseases.2. Similarities and differences between acute
stroke and acute myocardial infarction
Table 1 shows the key similarities between these two
illnesses and Table 2 the main differences. The pathophysiology
of acute myocardial infarction and acute ischemic stroke is in
principle similar: acute thrombotic occlusion of an artery causes
ischemic necrosis of the tissue perfused by that artery. However,Table 1 – Similarities between acute myocardial infarction an
Acute myocardial infa
Pathophysiology Arterial occlusionþis
Clinical picture Acute onset
Prognosis High mortality (if un
Effective treatment Reperfusion therapy
Thrombolytic treatment Early reperfusion ach
treated patients
Bleeding complicatio
Early reocclusion is
Pharmaco-invasive treatment
(thrombolysisþmechanical intervention)
Does not offer super
method if performed
Catheter-based thrombectomy Clearly established a
therapy.there is a critically important difference in the speed of necrosis
development and permanent function loss. While left ventricu-
lar (LV) function can be fully restored even after 2–4 h of
extensive ischemia and partial LV function recovery takes place
even after 12 h of myocardial ischemia, the full recovery of all
cerebral functions after moderate—large stroke is rather rare.
The etiology of acute myocardial infarction is rather uni-
form. Our previously published data showed, that cca 2% of
patients admitted for suspected ST segment elevation acute
myocardial infarction (STEMI) may have other condition
mimicking an infarction [1] and that cca 7% of STEMI patients
(mostly heavy smokers) do not have visible atherosclerosis but
rather ‘‘pure’’ thrombosis in an angiographically normal cor-
onary artery [2]. Thus over 90% of STEMI patients have the
same cause of their infarction: atherosclerotic plaque rupture
with superimposed in-situ arterial thrombosis. On the other
hand, the etiology of acute ischemic stroke is variable: throm-
boembolus from the heart (e.g. in atrial fibrillation), paradoxical
embolus from the venous system (via atrial septal defect or
foramen ovale patens), ‘‘arteriogenic’’ embolus (from aorta or
carotid artery), plaque rupture with in-situ thrombosis (similar
to myocardial infarction), lacunar (most likely caused by a
small artery occlusion, not detectable by current angiographic
techniques), cryptogenic (no cause revealed), etc.3. Reperfusion therapy
In the United States during 2009, only 4.5% of ischemic
strokes were treated by iv. thrombolysis [3]. Why only a very
small proportion of acute stroke patients receives reperfusion
therapy when such therapy is used nearly for all patients
with acute myocardial infarction? The reasons are listed in
Table 3 and Fig. 1.
There are approximately 40,000 hospital admissions for
stroke or TIA per year in the Czech Republic (10.5 milliond acute ischemic stroke.
rction Acute ischemic stroke
chemic necrosis Arterial occlusionþischemic necrosis
Acute onset
treated) High mortality (if untreated)
Reperfusion therapy
ieved in o50% of Early reperfusion achieved in o50% of
treated patients
ns may be fatal Bleeding complications may be fatal
frequent Early reocclusion is frequent
ior results to either
alone
Does not offer superior results to either
method if performed alone
s the most effective Emerging as the most effective therapy
Table 2 – Differences between acute myocardial infarction and acute ischemic stroke.
Acute myocardial infarction Acute ischemic stroke
Etiology Uniform: plaque ruptureþthrombosis in situ
in 90–95% patients, other causes are rare.
Multiple: cardioembolic, arterioembolic,
thrombosis in situ, lacunar, cryptogenic.
Arterial occlusive thrombus feasible for
catheter-based thrombectomy
Found in 95% of acute coronary angiograms Found only in cca 35% of acute CT-
angiograms
Time window symptom
onset—intervention start (to offer benefit
and not harm)
24 h (48 h in some patients) 3 h (8 h in some patients)
Reperfusion damage Only theoretical, clinically always
reperfusion benefit
Reperfusion damage (bleeding) is a real
clinical problem
Clinical picture Pain (dyspnoe) alerts the patient to call early
for help
Neurologic dysfunction plus absence of pain
causes late medical contacts in most pts.
Diagnostic method before reperfusion
therapy indication
ECG (fast, simple, cheap, can be done at the
site of first medical contact)
CT (takes more time, expensive, in-hospital)
Laboratory diagnostic marker Troponin None yet available
Contraindications for catheter-based
thrombectomy
None Intracranial bleeding or advanced ischemia
on CT
Proportion of hospitalized patients who
undergo reperfusion therapy
490% o10%
Table 3 – Possible explanations for low use of reperfusion therapy in acute stroke.
Disease related explanations Health care related explanations
Many acute strokes are not suitable for
reperfusion (e.g. hemorrhagic strokes)
Risks of reperfusion therapy are currently unacceptably high in
pts with small strokes or TIAs
Fast development of necrosis Many health professionals do not consider acute stroke as
‘‘superemergency’’ (are not aware of benefits of very early
reperfusion therapy)
Risk of intracerebral bleeding (hemorhagic
conversion of ischemic stroke)
Absence of alerting symptoms (e.g. pain)
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based thrombectomy (CBT) and 1600 of them by thromboly-
sis. Two most active Czech centers perform cca 30
catheter-based thrombectomy (CBT) interventions for
acute stroke annually, remaining centers between 5 and 15/
year. There are approximately 30,000 hospital admissions for
acute coronary syndromes (20,000 of them for acute myocar-
dial infarction) and majority of them undergo coronary
angiography with subsequent PCI or bypass surgery.
Twenty-two Czech cardiology centers perform cca 15,000 PCIs
for acute coronary syndromes per year. This discrepancy is
striking.4. Intravenous thrombolysis
The third International Stroke Trial (IST-3) randomized 3035
elderly (53% were 480 years) patients with acute ischemic
strokeo6 h from symptom onset in two groups: (A) 0.9 mg/kg
of intravenous rt-PA to a maximum of 90 mg (10% bolus with
the remainder over 1 h) or (B) control treatment. Unfavorable
outcome (death or disability by Oxford Handicap Score42) at
6 months was found in 63% (rt-PA) vs. 65% (control, p¼0.181).
Fatal or non-fatal symptomatic intracranial hemorrhage
within 7 days occurred in 104 (7%) patients in the rt-PA group
versus 16 (1%) in the control group. Early mortality was 11%(rt-PA) vs. 7% (control group, p¼0.001), total 6 months
mortality was equal in both groups (27%). This clearly
negative study is surprisingly interpreted as ‘‘despite the
early hazards, thrombolysis within 6 h improved functional
outcome, benefit did not seem to be diminished in elderly
patients’’, what is difficult to understand in such a high
quality journal as Lancet certainly is.
One comprehensive metaanalysis comparing iv. thrombo-
lysis versus conservative therapy for acute stroke [4] included
26 trials involving 7152 patients. The trials tested urokinase,
streptokinase, recombinant tissue plasminogen activator,
recombinant pro-urokinase or desmoteplase. Most data come
from trials that started treatment up to 6 h after stroke. About
55% of the data come from trials testing intravenous tissue
plasminogen activator. Thrombolytic therapy increased the
risk of symptomatic intracranial hemorrhage (OR 3.49, 95% CI
2.81–4.33) and death (OR 1.31, 95% CI 1.14–1.50). Thrombolytic
therapy significantly reduced the proportion of patients who
were dead or dependent (modified Rankin 3 to 6) at 3–6
months after stroke (odds ratio 0.81, 95% confidence interval
0.73–0.90). Treatment within o3 h of stroke appeared more
effective in reducing death or dependency (OR 0.71, 95% CI
0.52–0.96) with no statistically significant adverse effect on
death (OR 1.13, 95% CI 0.86–1.48). Antithrombotic drugs
given soon after thrombolysis may increase the risk of death.
Thus, when these data are critically interpreted, intravenous
100% patients (pts) with 
acute stroke
85% pts with ischemic 
stroke
40% pts presenting with 
moderate - large ischemic  
stroke
10% pts. presenting 
within <3 hours of  
symptom onset: 
reperfusion therapy 
30% pts. presenting late: 
reperfusion therapy not 
indicated
45% pts presenting with a 
minor stroke or TIA: 
reperfusion therapy not 
indicated (risks outweight 
benefits)
15% pts with hemorhagic 
stroke
Fig. 1 – Diagram showing why only a small minority of acute stroke patients undergo reperfusion therapy.
Fig. 2 – Angiography showing acute thrombotic occlusion of the medial cerebral artery (left, red arrow) with avascular
ischemic territory (left, yellow circle) before catheter-based thrombectomy and (right) after the successful procedure
performed with the Solitaires stent retriever. Normalization of the previously occluded vessel segment (red arrow, right) as
well as the distal perfusion (yellow circle, right) is clearly visible. (For interpretation of the references to color in this figure
legend, the reader is referred to the web version of this article.)
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reduce disability at the price of increasing mortality.
Even one of the two most positive thrombolytic trials [5]
did not show mortality benefit (17.3% three-months mortalityafter thrombolysis versus 20.5% mortality after placebo,
p¼0.30). This trial found a significant decrease in overall
unfavorable outcome (death or severe disability defined as
mRS 42 was found in 57% after thrombolysis versus 73%
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 1 1 1 – e 1 1 6 e115after placebo)—the difference caused by 13% absolute reduction
in permanent disability. Symptomatic intracranial (6.4% throm-
bolysis vs. 0.6% placebo) as well as overall fatal (2.9% thrombo-
lysis vs. 0.3% placebo) bleeding was higher after rt-PA.
The ECASS III trial [6] enrolled 821 patients treated
between 3 and 4.5 h after the onset of a stroke. Less patients
had an unfavorable outcome with alteplase than with pla-
cebo (48% vs. 55%; p¼0.04). The incidence of symptomatic
intracranial hemorrhage was higher with alteplase than with
placebo (2.4% vs. 0.2%; p¼0.008). Mortality did not differ
significantly between the alteplase and placebo groups
(7.7% and 8.4%, respectively; p¼0.68).
Another metaanalysis [7] included 3670 patients from 8
trials using rt-PA (ECASS III, EPITHET and 6 older trials) and
was focused on the time window between symptom onset
and start of thrombolysis. Favorable 3-month outcome was
defined as modified Rankin score 0–1. Mortality and clinically
relevant parenchymal hemorrhage was analyzed. All patients
were randomly allocated to alteplase or placebo. Favorable
3-month outcome increased as time delay decreased (p¼
0.0269) and no benefit of alteplase treatment was seen after
around 270 min. Adjusted odds of a favorable 3-month out-
come were 2.55 (95% CI 1.44–4.52) for 0–90 min, 1.64
(1.12–2.40) for 91–180 min, 1.34 (1.06–1.68) for 181–270 min,
and 1.22 (0.92–1.61) for 271–360 min in favor of the alteplase
group. Large parenchymal hemorrhage was seen in 5.2% of
patients assigned to alteplase and 1.0% of controls, with
no clear relation to time delays. Adjusted odds of mortality
increased with time delay (p¼0.0444) and were 0.78 (0.41–
1.48) for 0–90 min, 1.13 (0.70–1.82) for 91–180 min, 1.22
(0.87–1.71) for 181–270 min, and 1.49 (1.00–2.21) for 271–360
min. It is surprising, that even among a subgroup of patients
treated by iv. thrombolysis within 90 min from stroke onset
the trend to lower mortality is not significant and in all other
subgroups (treated after 490 min) there is a trend toward
increased mortality with thrombolytic treatment.5. Intra-arterial thrombolysis
Metaanalysis of 15 studies [8] on combined intravenousþ
intra-arterial thrombolytic therapy found 35.1% complete
recanalization rate, 17.9% mortality, 51.1% unfavorable out-
come (death or disability mRS 42 at 90 days) and 8.6%
symptomatic intracranial hemorrhage (proven hemorrhage
with an increase of NIHSS by Z4 points). Neither mortality
difference nor difference in symptomatic intracranial hemor-
rhage was found when combined lytic therapy was compared
to intravenous thrombolysis alone. Eight studies included
planned combination of iv.þia. lysis, while 7 studies included
only rescue ia. lysis. Only 5 studies used also mechanical
(catheter-based) revascularization techniques. Medial cere-
bral artery was the site of thrombus in 63% of cases. Patient
numbers per individual studies varied between 11 and 69, the
total number of patients in the metaanalysis was 559.
The mean age was 66 years, the mean baseline NIHSS was
17. The mean time delays were 135 min (symptoms—iv. lysis
start) and 88 min. (iv. lysis start—angiography).
The Interventional Management of Stroke (IMS 3) trial [9]
compared intravenous thrombolysis (tPA) alone vs. facilitatedintervention (iv. tPAþintra-arterial tPA or mechanical throm-
bectomy). The trial has suspended enrollment for futility
(even if the study continued, it would not show the hypothe-
sized result that facilitated intervention is superior to iv. tPA
alone). The IMS 3 was a phase 3, randomized, open-label trial
that was planned to enroll subjects with a National Institutes
of Health Stroke Scale (NIHSS) score of Z8 treated within
3 h—656 of the planned 900 patients have been enrolled.
The study was not put on hold because of safety concerns.
The main results have not yet been published.
These data on combined therapy demonstrate, that there
is no benefit from facilitated intervention (iv. thrombolysis
followed by ia. thrombolysis7catheter intervention) over iv.
thrombolysis alone in acute stroke. This is very similar to the
situation in acute myocardial infarction 25 years ago (intra-
coronary thrombolysis was not superior to intravenous
thrombolysis) or more recently (facilitated PCI was not shown
to be superior in several trials).6. Catheter-based thrombectomy (CBT)
A few years ago CBTwas performed with bulky devices and a
significant risk of complications was present. In the last 3–5
years several new clot retrieval devices (stent retrievers) have
been introduced and received CE mark for the use in
European patients. These devices (e.g. Solitaires or Penum-
bras) are something between a tiny self expanding stent and
a soft ‘‘spider-web-like’’ basket for clot removal and the risks
of complications with this latest generation stent retrievers
are much smaller, while their success rates are higher.
Detailed information about CBT was published in the JACC
white paper [10].
The Penumbra Pivotal Stroke Trial [11] included 125
patients mostly pre-treated by thrombolysis, with mean
NIHSS 17.6 and demonstrated 81.6% recanalization rate.
However, clinical outcomes were not different (or were even
worse) from previous thrombolytic trials: 32.8% 90-day mor-
tality, 75% unfavorable outcome (death or disability) and
11.2% symptomatic intracranial hemorrhage.
A recently published single center experience [12] with 104
patients treated with the Solitaires stent retrieval, 75% of them
received also thrombolysis. The recanalization rate was 78%.
The mean NIHSS decreased from 15.3 (before) to 7.8 (after
treatment). Mortality was 16% (anterior circulation) and 47.8%
(posterior circulation). Intracranial bleeding occurred in 8%.
Another recent multicenter retrospective review [13]
included 237 patients (mean age 64 years; mean baseline
NIHSS 15) with acute proximal intracranial anterior circula-
tion occlusion, endovascular treatment initiated 48 h (mean
15 h) from time last seen well. The treatment selection was
strictly based on MRI or CT perfusion imaging. Successful
revascularization was achieved in 74%. Parenchymal hema-
toma occurred in 9%. The 90-day mortality rate was 21.5%
and unfavorable outcome was in 55%.
The most recent metaanalysis [14] of CBT registries iden-
tified 16 eligible published studies: 4 on the Merci device
(n¼357), 8 on the Penumbra system (n¼455), and 4 on stent-
retrievers Solitaires or Trevos (n¼113). The mean procedural
duration for Merci was 120 min. The mean puncture to
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retrievers 54.7 min. Successful recanalization was achieved in
59.1% (Merci), 86.6% (Penumbra) and 92.9% (stent-retrievers).
Functional independence (mRS r2) was achieved in 31.5%
(Merci), 36.6% (Penumbra) and 46.9% (stent-retrievers). The 3-
month mortality rate was 37.8% in the MD studies, 20.7% in
the PS studies, and 12.3% in RS studies. This study demon-
strated improved outcomes after CBT when performed with
the latest generation of stent-retrievers.
A recent study [15] demonstrated, that even stroke caused
by the acute occlusion of the internal carotid artery (with
only 17% recanalization rate and 55% mortality rate when
treated by thrombolysis) can be effectively treated by CBT:
successful revascularization of extracranial internal carotid
artery with acute stent implantation was achieved in 95% of
patients. The intracranial recanalization was achieved in 61%
of patients, who had simultaneous intracranial artery occlu-
sion. The mortality rate was 13.6% at 90 days and the
unfavorable outcome (mRS42) 59%.
These data show, that latest generation of stent retrievers
(Fig. 2) is able to recanalize 470% of occluded intracranial
arteries—approximately twice more compared to thrombolysis.
However, it is not yet known whether this translates to better
clinical outcomes. The sufficient data on outcomes after primary
CBT (without thrombolysis) are still missing and trials comparing
iv. thrombolysis versus primary CBT are urgently needed.7. Future: how to improve acute stroke
outcomes?
Facing the above mentioned questionable benefits from
intravenous thrombolysis (versus conservative treatment) in
acute stroke and absence of any benefits from intra-arterial
thrombolysis (versus intravenous lysis alone) the future trials
in acute stroke must follow the way paved by acute
myocardial infarction trials: the future trials should compare
intravenous thrombolysis alone versus catheter-based
mechanical intervention alone (without lytics) for occlusion
of major cerebral arteries. If such trials would demonstrate
superiority of catheter-based thrombectomy, we can face in
future similar revolution in acute stroke treatment as we
have been facing in acute MI treatment in the past years.
Nevertheless, irrespective of the trials results, the most
important is to prevent acute strokes—and this field is much
more successful already today. When the acute stroke occurs
despite the preventive measures, the critical value of every
minute shortening the delay to reperfusion therapy is
essential. The continuous education should be focused on
both—the wide population knowledge of stroke symptoms
and the critical role of time and also to health care profes-
sionals, who must change their passive attitude to stroke
treatment.Acknowledgements
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